HilleVax, Inc. (NASDAQ:HLVX) Short Interest Update

HilleVax, Inc. (NASDAQ:HLVX) was the recipient of a significant decline in short interest in the month of March. As of March 31st, there was short interest totalling 448,200 shares, a decline of 5.6% from the March 15th total of 474,900 shares. Based on an average daily volume of 124,700 shares, the days-to-cover ratio is presently 3.6 days. Approximately 2.9% of the shares of the company are short sold.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and set a $28.00 target price on shares of HilleVax in a report on Thursday, March 21st.

HilleVax Stock Down 3.7 %

Shares of HLVX opened at $12.53 on Thursday. The firm has a market cap of $622.99 million, a P/E ratio of -4.12 and a beta of 0.65. HilleVax has a 12 month low of $9.94 and a 12 month high of $20.22. The stock’s 50 day moving average is $16.15 and its two-hundred day moving average is $14.63. The company has a current ratio of 10.62, a quick ratio of 10.62 and a debt-to-equity ratio of 0.10.

HilleVax (NASDAQ:HLVX) last issued its quarterly earnings results on Wednesday, March 20th. The company reported ($0.78) EPS for the quarter, topping the consensus estimate of ($0.80) by $0.02. Analysts predict that HilleVax will post -3.22 earnings per share for the current fiscal year.

Insider Buying and Selling

In other HilleVax news, major shareholder Life Sciences X. L.P. Frazier purchased 8,850 shares of the business’s stock in a transaction that occurred on Thursday, April 4th. The shares were bought at an average price of $14.50 per share, for a total transaction of $128,325.00. Following the acquisition, the insider now owns 8,544,187 shares in the company, valued at $123,890,711.50. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In related news, major shareholder Life Sciences X. L.P. Frazier purchased 8,850 shares of the business’s stock in a transaction on Thursday, April 4th. The shares were bought at an average cost of $14.50 per share, with a total value of $128,325.00. Following the transaction, the insider now owns 8,544,187 shares of the company’s stock, valued at $123,890,711.50. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Aditya Kohli sold 6,000 shares of the business’s stock in a transaction dated Friday, April 5th. The shares were sold at an average price of $14.44, for a total value of $86,640.00. Following the completion of the transaction, the director now directly owns 789,776 shares of the company’s stock, valued at approximately $11,404,365.44. The disclosure for this sale can be found here. Insiders sold 78,039 shares of company stock valued at $986,464,242 over the last quarter. 29.30% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of HLVX. Ameritas Investment Partners Inc. boosted its holdings in HilleVax by 80.3% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 1,753 shares of the company’s stock worth $30,000 after buying an additional 781 shares during the last quarter. Rhumbline Advisers boosted its stake in shares of HilleVax by 3.2% in the third quarter. Rhumbline Advisers now owns 27,414 shares of the company’s stock worth $369,000 after acquiring an additional 838 shares during the last quarter. Federated Hermes Inc. increased its position in shares of HilleVax by 80.6% during the third quarter. Federated Hermes Inc. now owns 2,113 shares of the company’s stock worth $28,000 after purchasing an additional 943 shares in the last quarter. Tower Research Capital LLC TRC increased its position in shares of HilleVax by 57.4% during the first quarter. Tower Research Capital LLC TRC now owns 2,587 shares of the company’s stock worth $43,000 after purchasing an additional 943 shares in the last quarter. Finally, Royal Bank of Canada lifted its holdings in HilleVax by 28.9% in the 2nd quarter. Royal Bank of Canada now owns 4,779 shares of the company’s stock valued at $82,000 after purchasing an additional 1,072 shares in the last quarter. Institutional investors and hedge funds own 86.42% of the company’s stock.

HilleVax Company Profile

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. The company develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus and related illness. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.